Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM

Trial Profile

A Proof-of-Concept and Dose-Ranging Study Investigating the Efficacy and Safety of HTD1801 in Adults With NASH and T2DM

Recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs HTD 1801 (Primary)
  • Indications Non-alcoholic steatohepatitis
  • Focus Proof of concept; Therapeutic Use
  • Sponsors HighTide Biopharma
  • Most Recent Events

    • 26 Nov 2018 Status changed from not yet recruiting to recruiting.
    • 07 Nov 2018 Planned initiation date changed from 31 Oct 2018 to 30 Nov 2018.
    • 10 Sep 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top